The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 806 participants.
Also called NCT04781114
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 806 participants
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Registry
-
NCT04781114
-
- Other papers using this trial's data
- Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04781114. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-23 (actual); primary completion 2022-05-25 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia
- Condition
- Hyperlipemia
- Intervention (Drug)
- JS002
- Intervention (Drug)
- Placebo
- Lead sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Record details
- Record id
cardio:ct-nct04781114- Content hash
405184fb559d4beba1ef0a8eb08405f9af3e6c181ceb79aa161cbe179d8fa4ef